vs
Side-by-side financial comparison of GRID DYNAMICS HOLDINGS, INC. (GDYN) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
GRID DYNAMICS HOLDINGS, INC. is the larger business by last-quarter revenue ($104.1M vs $103.7M, roughly 1.0× Twist Bioscience Corp). GRID DYNAMICS HOLDINGS, INC. runs the higher net margin — -1.4% vs -29.4%, a 28.0% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 3.7%).
Escape Dynamics, Inc. was a Colorado-based technology company that operated 2010–2015 focused on bringing to market single-stage-to-orbit reusable electromagnetically powered spaceplanes.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
GDYN vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $104.1M | $103.7M |
| Net Profit | $-1.5M | $-30.5M |
| Gross Margin | 34.8% | 52.0% |
| Operating Margin | 61.7% | -31.7% |
| Net Margin | -1.4% | -29.4% |
| Revenue YoY | 3.7% | 16.9% |
| Net Profit YoY | -150.6% | 3.4% |
| EPS (diluted) | $-0.02 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.1M | — | ||
| Q4 25 | $106.2M | $103.7M | ||
| Q3 25 | $104.2M | — | ||
| Q2 25 | $101.1M | — | ||
| Q1 25 | $100.4M | — | ||
| Q4 24 | $100.3M | — | ||
| Q3 24 | $87.4M | — | ||
| Q2 24 | $83.0M | — |
| Q1 26 | $-1.5M | — | ||
| Q4 25 | $306.0K | $-30.5M | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $2.9M | — | ||
| Q4 24 | $4.5M | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $-817.0K | — |
| Q1 26 | 34.8% | — | ||
| Q4 25 | 34.0% | 52.0% | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 34.1% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.9% | — | ||
| Q3 24 | 37.4% | — | ||
| Q2 24 | 35.6% | — |
| Q1 26 | 61.7% | — | ||
| Q4 25 | 0.5% | -31.7% | ||
| Q3 25 | -0.2% | — | ||
| Q2 25 | -0.1% | — | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | -1.4% | — | ||
| Q4 25 | 0.3% | -29.4% | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | -1.0% | — |
| Q1 26 | $-0.02 | — | ||
| Q4 25 | $0.01 | $-0.50 | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.06 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $0.06 | — | ||
| Q3 24 | $0.05 | — | ||
| Q2 24 | $-0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $327.5M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $530.1M | $456.1M |
| Total Assets | $605.0M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $327.5M | — | ||
| Q4 25 | $342.1M | $197.9M | ||
| Q3 25 | $338.6M | — | ||
| Q2 25 | $336.8M | — | ||
| Q1 25 | $325.5M | — | ||
| Q4 24 | $334.7M | — | ||
| Q3 24 | $231.3M | — | ||
| Q2 24 | $256.0M | — |
| Q1 26 | $530.1M | — | ||
| Q4 25 | $542.1M | $456.1M | ||
| Q3 25 | $537.7M | — | ||
| Q2 25 | $532.2M | — | ||
| Q1 25 | $517.4M | — | ||
| Q4 24 | $517.8M | — | ||
| Q3 24 | $400.2M | — | ||
| Q2 24 | $388.4M | — |
| Q1 26 | $605.0M | — | ||
| Q4 25 | $612.9M | $638.1M | ||
| Q3 25 | $613.2M | — | ||
| Q2 25 | $608.9M | — | ||
| Q1 25 | $590.9M | — | ||
| Q4 24 | $592.2M | — | ||
| Q3 24 | $477.3M | — | ||
| Q2 24 | $443.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $9.9M | $-24.8M | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $14.4M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $7.1M | — | ||
| Q3 24 | $9.2M | — | ||
| Q2 24 | $10.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $6.1M | $-34.8M | ||
| Q3 25 | $2.9M | — | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | $6.0M | — | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $5.9M | — | ||
| Q2 24 | $8.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | -33.5% | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 10.1% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 9.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 9.6% | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 32.34× | — | ||
| Q3 25 | 5.92× | — | ||
| Q2 25 | 2.73× | — | ||
| Q1 25 | 3.21× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GDYN
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
